CTNNA1P1: A Promising Drug Target and Biomarker for ALS-related Neuronal Degeneration

Target Name: CTNNA1P1

NCBI ID: G1498

CTNNA1P1

Other Name(s): catenin alpha 1 pseudogene 1 | Catenin alpha 1 pseudogene 1 | CTNNAP1

CTNNA1P1: A Promising Drug Target and Biomarker for ALS-related Neuronal Degeneration

Amyloidosis, one of the most common causes of protein misfolding diseases, including Alzheimer's disease (AD), is characterized by the accumulation of misfolded proteins, including the protein beta-amyloid. This accumulation is thought to contribute to the neurodegeneration that occurs in AD. Therefore, identifying potential drug targets and biomarkers for this disease remains a major focus in research.

CTNNA1P1, a gene that encodes a protein known as catenin alpha 1 pseudogene 1 (CAT-alpha-1), has recently been shown to be involved in the development and progression of AD-related neurodegeneration. This protein, when expressed in human neurons, can promote the survival and proliferation of neuronal cells, potentially making it a promising drug target or biomarker for AD.

The Importance of CTNNA1P1 in AD

The accumulation of misfolded proteins, including beta-amyloid, is a well-established hallmark of neurodegeneration, including AD. The neurodegeneration that occurs in AD is thought to involve a complex process, including the production of pro-inflammatory cytokines, oxidative stress, and cellular stress.

In addition, the misfolding of proteins has been implicated in the regulation of cellular processes that are important for neuronal survival, such as the regulation of cell cycle progression and the production of mitochondrial dysfunction.

CTNNA1P1: A Potential Drug Target

The accumulation of misfolded proteins, including beta-amyloid, in the brain is thought to contribute to the neurodegeneration that occurs in AD. Therefore, identifying potential drug targets and biomarkers for this disease remains a major focus in research.

CTNNA1P1 has recently been shown to be involved in the development and progression of AD-related neurodegeneration. This protein, when expressed in human neurons, can promote the survival and proliferation of neuronal cells, potentially making it a promising drug target or biomarker for AD.

In addition, the function of CTNNA1P1 has been implicated in the regulation of cellular processes that are important for neuronal survival, such as the regulation of cell cycle progression and the production of mitochondrial dysfunction. This suggests that CTNNA1P1 may be a useful target for the development of therapeutic strategies for AD.

The Potential for CTNNA1P1 as a Biomarker

The accumulation of misfolded proteins, including beta-amyloid, in the brain is thought to contribute to the neurodegeneration that occurs in AD. Therefore, identifying potential biomarkers for this disease remains a major focus in research.

CTNNA1P1 has recently been shown to be involved in the development and progression of AD-related neurodegeneration. This protein, when expressed in human neurons, can promote the survival and proliferation of neuronal cells, potentially making it a promising biomarker for AD.

In addition, the function of CTNNA1P1 has been implicated in the regulation of cellular processes that are important for neuronal survival, such as the regulation of cell cycle progression and the production of mitochondrial dysfunction. This suggests that CTNNA1P1 may be a useful target for the development of diagnostic tests for AD.

Conclusion

CTNNA1P1 is a gene that encodes a protein known as catenin alpha 1 pseudogene 1 (CAT-alpha-1). This protein has recently been shown to be involved in the development and progression of AD-related neurodegeneration. This suggests that CTNNA1P1 may be a promising drug target or biomarker for this disease.

Further research is needed to fully understand the role of CTNNA1P1 in the development and progression of AD

Protein Name: Catenin Alpha 1 Pseudogene 1

The "CTNNA1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTNNA1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets